Drug Profile

CNTY 106

Alternative Names: CNTY-106

Latest Information Update: 22 Nov 2022

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Century Therapeutics
Class Antineoplastics; Gene therapies; Immunotherapies; Induced pluripotent stem cell therapies; NKT cell therapies; T lymphocyte cell therapies
Mechanism of Action Immunologic cytotoxicity; Natural killer cell replacements; T lymphocyte replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

19 Oct 2022 Early research in Multiple myeloma in USA (Parenteral) (Century Therapeutics pipeline, October 2022)
19 Oct 2022 Century Therapeutics plans to file an IND application for Hematological malignancies in 2024 (Century Therapeutics pipeline, October 2022)
10 Jan 2022 Century Therapeutics and Bristol Myers Squibb enters into a collaboration agreement to develop CNTY 106

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com